Vatalanib

What is Vatalanib?

Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.

Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.

Questions and answers on "Vatalanib"

Need to know what degree of side effects is of the drug --LEE011--- that I am about to get in my clinical trial? ---I have secondary progressive MS...

doctor1 MD

Hi,

Till now the clinical trial for LEE011 shows that it has minor side effects only which you have mentioned here. This is why they are switching...

Read Full Thread   Ask a Doctor Now

Recent questions on  Vatalanib

doctor1 MD

Need to know what degree of side effects is of the drug --LEE011--- that I am about to get in my clinical trial? ---I have secondary progressive MS...

Ask Question
Doctor Image
MD

Hi, I am Dr. Andrew Rynne (Family Physician). I will be guiding you through the process. Please write your question below.

Related Disease & Conditions
Related Drugs/Medications
Related Treatment/Therapy